Default company panoramic image
E4e12bc1 dc31 488d 9cdd 5b11502d4085

Delta One Therapeutics

We hold a patented technology platform potentially capable of achieving complete remissions in Leukemia patients,with no severe side effects

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Lisbon Street, Lisbon, ME, US
  • Currency EUR
  • Founded March 2012
  • Employees 2

Company Summary

Delta One Therapeutics is a biotechnology startup company focused on developing state-of-the-art personalized treatments targeting cancer and chronic viral diseases. After 5 years of pioneering research, we created a new technology platform that can generate autologous and heterologous cellular immune therapies for clinical applications. The absence of severe associated side effects is our most distinctive and unique feature.


  • Default avatar
    Daniel Correia

    Daniel Correia was the author of the discovery that led to the development of the DOT cell technology. He has been working since 2007 at Instituto de Medicina Molecular in Lisbon, in the field of cancer immunology. For these studies, he received his PhD in 2012. As first author, he has published four scientific papers in international peer-reviewed, high impact factor scientific journals. He has been distinguished with several awards.

  • Default avatar
    Diogo Anjos

    Diogo Anjos is an Engineer and worked as a research assistant at the university where he graduated from. Afterwards he moved to Siemens where he dealt with a gigantic change management process which lead to the birth of Nokia Siemens Networks and allow him to quickly ascend in the new company as project manager. Before entering IE Business School in Madrid, where he would finish his MBA with distinction, Diogo worked as a management consultant.

Previous Investors

  • Default avatar
    Default avatar
    Busy Angels SGPS
    Default avatar
    Portugal Capital Ventures S.A.